Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1956

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 1956
---
 February 5, 2025, the Company entered into the SPA, with participation from a member of the Company’s Board and a single
institutional investor, for the purchase and sale of (i) 2,551,020 shares of our common stock or common stock equivalents in lieu thereof;
and (ii) February 2025 Common Warrants to purchase up to 2,551,020 shares of common stock, at a combined public offering price of $1.96
per share and warrant. In connection with this offering, the Company received net proceeds of approximately $4.5 million. Additionally,
since December 31, 2024, the Company received net proceeds from the exercise of the remaining Series A Preferred Warrants, the collection
of subscriptions receivable and ELOC fundings of approximately $2.5 million. Any estimate as to how long the Company expects the net proceeds
from the ELOC funding may fund the Company’s operations is based on assumptions that may prove to be wrong, and the Company could
use its available capital resources sooner than its current expectations. Changing circumstances, some of which may be beyond the Company’s
control, could result in less cash and cash equivalents available to fund operations or cause the Company to consume capital significantly
faster than currently anticipated, and the Company may need to seek additional funds from additional sources sooner than planned.

Because of the numerous risks
and uncertainties associated with research, development and commercialization of pharmaceutical drug products, the Company is unable to
estimate the exact amount of its operating capital requirements. The Company’s future funding requirements will depend on many factors,
including, but not limited to those listed under “Factors Affecting Our Performance” above.

Identifying potential product
candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes many
years to complete, and the Company may never generate the necessary data or results required to obtain marketing approval and achieve
product sales. In addition, the Company’s product candidates, if approved, may not achieve commercial success. Commercial revenues,
if any, will be derived from sales of product candidates that the Company does not expect to be commercially available in the near term,
if at all. Accordingly, the Company will need to continue to rely on additional financing to achieve its business objectives. Adequate
additional financing may not be available to the Company on acceptable terms, or at all. To the extent that the Company raises additional
capital through the sale of equity or convertible debt securities, the